ストックスクリーナーアプリを入手
11.53
0.79%
0.09
前日終値:
$11.44
開ける：
$11.44
24時間の取引高:
1.58M
Relative Volume:
0.43
時価総額：
$1.53B
収益：
-
当期純損益:
$-766.97M
株価収益率:
-1.5052
EPS:
-7.66
ネットキャッシュフロー:
$-646.43M
1週間 パフォーマンス:
+20.73%
1か月 パフォーマンス:
+45.03%
6か月 パフォーマンス:
-26.04%
1年 パフォーマンス:
-71.29%
1日の値動き範囲:
$11.13
$11.65
1週間の範囲:
$9.70
$11.71
52週間の値動き範囲:
$7.48
$44.28
Biohaven Ltd Stock (BHVN) Company Profile
BHVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
11.53 | 1.52B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | ダウングレード | UBS | Buy → Neutral |
| 2025-11-06 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 開始されました | Citigroup | Buy |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-05-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-09-16 | 開始されました | Jefferies | Buy |
| 2024-09-04 | 開始されました | Bernstein | Outperform |
| 2024-07-24 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2023-12-22 | 開始されました | H.C. Wainwright | Buy |
| 2023-12-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-01-24 | 開始されました | SVB Securities | Outperform |
| 2023-01-04 | 開始されました | JP Morgan | Overweight |
| 2022-12-02 | 開始されました | BTIG Research | Buy |
| 2022-10-26 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 開始されました | Piper Sandler | Overweight |
| 2022-08-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-05-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-10 | ダウングレード | UBS | Buy → Neutral |
| 2021-08-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-03-11 | 開始されました | UBS | Buy |
| 2020-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-17 | 開始されました | Cowen | Outperform |
| 2020-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2019-11-22 | 開始されました | Wedbush | Outperform |
| 2019-06-25 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-05-06 | 開始されました | Goldman | Buy |
| 2019-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 繰り返されました | Needham | Buy |
| 2018-07-03 | 繰り返されました | Needham | Buy |
| 2018-07-02 | 繰り返されました | Needham | Buy |
| 2018-04-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-12-15 | 開始されました | Canaccord Genuity | Buy |
| 2017-10-03 | 繰り返されました | Needham | Buy |
すべてを表示
Biohaven Ltd (BHVN) 最新ニュース
Bellevue Group AG Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Certain options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain warrants of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Biohaven Ltd. $BHVN Position Trimmed by Redmile Group LLC - MarketBeat
Armistice Capital LLC Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Biohaven jumps on early-stage data for antibody drug conjugate combo - Seeking Alpha
Why Biohaven (BHVN) Is Up 16.2% After New Trop2 ADC Combo Data At ESMO IO 2025 – And What's Next - simplywall.st
Biohaven stock jumps after promising cancer drug results By Investing.com - Investing.com Nigeria
Biohaven stock jumps after promising cancer drug results - Investing.com India
Biohaven presents data for BHV-1510 at ESMO - TipRanks
Biohaven reports promising results for cancer drug BHV-1510 By Investing.com - Investing.com South Africa
Biohaven shares cancer drug trial results at European oncology meeting - StreetInsider
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress - PR Newswire
Biohaven (NYSE:BHVN) Stock Price Down 5%What's Next? - MarketBeat
Norges Bank Makes New $12.74 Million Investment in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (NYSE:BHVN) Trading Up 8.8%Still a Buy? - MarketBeat
Responsive Playbooks and the BHVN Inflection - news.stocktradersdaily.com
Biohaven Ltd. $BHVN Position Lowered by Panagora Asset Management Inc. - MarketBeat
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders - MSN
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% - Eastern Progress
Why Biohaven Ltd. stock could rally in 2025Jobs Report & Weekly Consistent Profit Watchlists - Newser
HC Wainwright Comments on Biohaven FY2029 Earnings - MarketBeat
Will Biohaven Ltd. Common Shares stock beat international competition2025 Institutional Moves & Weekly Setup with High ROI Potential - Newser
Will Biohaven Ltd. stock beat EPS estimatesJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Does Biohaven Ltd. stock trade at a discount to peersWeekly Trend Summary & Stock Portfolio Risk Management - Newser
Is Biohaven Ltd. Common Shares stock dividend growth reliableJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Biohaven (NYSE:BHVN) Shares Gap DownTime to Sell? - MarketBeat
Why Biohaven Ltd. Common Shares stock signals breakout potentialMarket Growth Summary & Long-Term Safe Investment Ideas - Newser
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Biohaven to Neutral From Buy, Adjusts Price Target to $11 From $30 - marketscreener.com
Biohaven (BHVN) Receives Downgrade and Price Target Cut by HC Wa - GuruFocus
Biohaven downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
JPMorgan Chase & Co. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Capital Fund Management S.A. Grows Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Is Biohaven Ltd. Common Shares stock a defensive play amid uncertaintyPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Why Biohaven Ltd. stock appeals to dividend seekersJuly 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - Newser
Why Is Biohaven Ltd. (BHVN) Stock Down Today? - Meyka
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
What downside risks could hit Biohaven Ltd. Common Shares stockWeekly Trade Recap & Pattern Based Trade Signal System - Newser
Biohaven (BHVN): Evaluating Valuation After UBS Downgrade and Shifting Analyst Sentiment - simplywall.st
Biohaven Ltd. $BHVN Stake Boosted by Geode Capital Management LLC - MarketBeat
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost - Yahoo Finance
Why Biohaven Ltd. Common Shares stock is a strong analyst pickCEO Change & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
The Bull Case For Biohaven (BHVN) Could Change Following Recent Analyst Downgrades - simplywall.st
RSI Check: Why retail investors favor Biohaven Ltd. stockM&A Rumor & Consistent Profit Trading Strategies - moha.gov.vn
Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy? - AOL.com
Can Biohaven Ltd. stock outperform in 2025 bull market2025 Market WrapUp & Long Hold Capital Preservation Plans - moha.gov.vn
UBS Downgrades Biohaven (BHVN) - MSN
Biohaven downgraded to Neutral from Buy at UBS - MSN
Understanding the Setup: (BHVN) and Scalable Risk - news.stocktradersdaily.com
UBS Downgrades Biohaven (BHVN) and Lowers Price Target | BHVN St - GuruFocus
Biohaven Ltd (BHVN) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):